Clement Robert, Arnaud de la Fouchardière, Nicolas Gadot, Manale El Kharbili, Emmanuelle Danty-Berger, Shoukat Dedhar, Laetitia Barbollat-Boutrand, Paul C. McDonald, François Le Naour, Ingrid Masse, Tiffany Witkowski, Françoise Degoul, Odile Berthier-Vergnes, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, University of Colorado, University of Colorado [Boulder], Imagerie Moléculaire et Thérapie Vectorisée (IMTV), ITMO ' Technologies pour la Santé '-Cancéropôle CLARA-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université d'Auvergne - Clermont-Ferrand I (UdA), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Léon Bérard [Lyon], British Columbia Cancer Agency, Microenvironnement et Physiopathologie de la Differenciation, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Nationale Contre le Cancer (Comites de l'Ardeche et de la Savoie), Ligue Nationale de Recherche Contre le Cancer (Comite de Savoie) : ARC fundation, Université d'Auvergne - Clermont-Ferrand I (UdA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Cancéropôle CLARA-ITMO ' Technologies pour la Santé ', Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)
// Manale El Kharbili 1, 2, 3, 4 , Clement Robert 1, 2, 3 , Tiffany Witkowski 5, 6 , Emmanuelle Danty-Berger 7 , Laetitia Barbollat-Boutrand 1, 2, 3 , Ingrid Masse 1, 2, 3 , Nicolas Gadot 8 , Arnaud de la Fouchardiere 9 , Paul C. McDonald 10 , Shoukat Dedhar 10 , Francois Le Naour 11, 12 , Francoise Degoul 5, 6 , Odile Berthier-Vergnes 1, 2, 3 1 Universite de Lyon, Lyon, France 2 Universite Lyon 1, Lyon, France 3 CNRS, UMR5534, Centre de Genetique et de Physiologie Moleculaire et Cellulaire, Villeurbanne, France 4 Current address: Department of Dermatology, University of Colorado, Aurora, Colorado, USA 5 Clermont Universite, Universite d’Auvergne, Imagerie Moleculaire et Therapie Vectorisee, Clermont-Ferrand, France 6 Inserm, U990, Clermont-Ferrand, France 7 Laboratoire CarMeN (INSERM 1060, INRA1397, INSA), Universite Lyon 1, Lyon, France 8 Universite Lyon 1, Federation de Recherche Sante Lyon-Est, ANIPATH, Faculte Laennec, Lyon, France 9 Departement de Biopathologie, Centre Leon Berard, Lyon, France 10 Department of Integrative Oncology, British Columbia Cancer Research Center, Vancouver, Canada 11 INSERM U602, Villejuif, France 12 Current address: INSERM U1193, Hopital Paul Brousse, Villejuif, France Correspondence to: Odile Berthier-Vergnes, email: odile.berthier-vergnes@univ-lyon1.fr Keywords: melanoma, matrix, integrin, tetraspanin 8, ILK Received: November 09, 2016 Accepted: January 09, 2017 Published: February 04, 2017 ABSTRACT Melanoma is well known for its propensity for lethal metastasis and resistance to most current therapies. Tumor progression and drug resistance depend to a large extent on the interplay between tumor cells and the surrounding matrix. We previously identified Tetraspanin 8 (Tspan8) as a critical mediator of melanoma invasion, whose expression is absent in healthy skin. The present study investigated whether Tspan8 may influence cell-matrix anchorage and regulate downstream molecular pathways leading to an aggressive behavior. Using silencing and ectopic expression strategies, we showed that Tspan8-mediated invasion of melanoma cells resulted from defects in cell-matrix anchorage by interacting with β1 integrins and by interfering with their clustering, without affecting their surface or global expression levels. These effects were associated with impaired phosphorylation of integrin-linked kinase (ILK) and its downstream target Akt-S473, but not FAK. Specific blockade of Akt or ILK activity strongly affected cell-matrix adhesion. Moreover, expression of a dominant-negative form of ILK reduced β 1 integrin clustering and cell-matrix adhesion. Finally, we observed a tumor-promoting effect of Tspan8 in vivo and a mutually exclusive expression pattern between Tspan8 and phosphorylated ILK in melanoma xenografts and human melanocytic lesions. Altogether, the in vitro, in vivo and in situ data highlight a novel regulatory role for Tspan8 in melanoma progression by modulating cell-matrix interactions through β1 integrin-ILK axis and establish Tspan8 as a negative regulator of ILK activity. These findings emphasize the importance of targeting Tspan8 as a means of switching from low- to firm-adhesive states, mandatory to prevent tumor dissemination.